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Multiple Osteochondromas (MO) is a disease of benign bony growths with a low incidence of malignant transformation.
Secondary chondrosarcoma in children is rare even in children with MO. Making a diagnosis of malignancy in low-grade cartilage
tumors is challenging and requires consideration of clinical, radiographic, and histopathological factors. We report two cases of
skeletallyimmaturepatientswithMOwhopresentedwithrapidlyenlargingandradiographicallyaggressivelesionsconsistentwith
malignant transformation. Both underwent allograft reconstruction of the involved site with no signs of recurrence or metastatic
disease at a minimum of four-year follow-up.
1.Introduction
Multiple Osteochondromas (MO) is an autosomal dominant
disease of benign osseous tumors occurring primarily in the
metaphyseal regions of the appendicular long bones and
the ﬂat bones of the axial skeleton. The risk of malignant
progression has been estimated to range from 1 to 25% of
patients with MO [1–6], though more likely at the lower end
of this range [7]. The cases of chondrosarcoma reported in
association with MO are typically found in patients between
the third and ﬁfth decade [2, 8]. Chondrosarcoma is rare in
children, including children and adolescents with MO [8–
11].
Approximately 80% of patients with MO have an iden-
tiﬁable mutation in one of two genes, EXT1 and EXT2,
on chromosomes 8 and 11, respectively[12–21]. These two
genes are believed to code for transmembrane glycosyltrans-
ferases responsible, at least in part, for the regulation of
heparan sulfate proteoglycans involved in cell signaling and
chondrocyteproliferationanddiﬀerentiation[12,13,22,23].
The pathogenesis of osteochondromas is unclear. A routine
aberrancyintheperichondrialgrooveofRanvier[24]ma ybe
the functional hit that when coupled with haploinsuﬃcency
of EXT1 or EXT2 provides the second-hit necessary for
development of an osteochondroma[12]. For patients with
MO, the haploinsuﬃciency is due to a mutation present in
all chondrocytes; for those with isolated osteochondromas,
the mutation may originate in a chondrocyte residing in
the abnormal region of the groove of Ranvier. The loss of
heterozygosity for the EXT loci that occurs in chondrosar-
comas[15, 25, 26] supports a two-hit mutational model at
EXT1 and EXT2 for malignant transformation.
Diagnosing sarcomatous progression of an osteochon-
droma is challenging, as the histology may reveal only subtle
changes of malignancy[2, 27]. Additional factors supporting
a diagnosis of malignancy include growth beyond that
expected given the age of the patient; in adults, a thickened
cartilage cap; and imaging evidence of an aggressive lesion,2 Sarcoma
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Figure 1: (a) Axial MRI images of the iliac mass reveal its enlarged
cartilage cap of 5-6cm thickness and the nodular or ring and arc
enhancement (large arrow). (b) Coronal MRI images reveal the
enlarged cartilage cap, nodular or ring and arc enhancement (large
arrow), and invasion of the inner table cortex by tumor (small
arrow).
including erosion of surrounding bony structures, punctate
calciﬁcations within the surrounding soft tissues [2, 28]o r
cartilagecap[29],andhighmetabolicactivityinthecartilage
as evidenced by uptake of gadolinum on T2 MRI[30, 31].
Low-grade cartilage malignancies should have low local and
metastatic recurrence risk [32]. However, failure to make the
diagnosis leads to a delay in treatment, potentially aﬀecting
long-term prognosis[32].
2.MaterialsandMethods
We report two pediatric patients with MO with sarcomatous
progression to illustrate the challenges in diﬀerentiating
benign osteochondroma from chondrosarcoma.
2.1. Case 1. An otherwise healthy 11-year-old male with
a family history of MO and multiple osteochondromas
(a)
(b) (c)
Figure 2: (a) Low-power micrograph (10×) of the low-grade
chondrosarcoma: H&E stained normal cartilage (left) is separated
by a ﬁbrous band from an expansile nodule of malignant cartilage
(right). (b) 40× photomicrograph reveals a region of typical
benign cartilage of an osteochondroma, with cells of similar sizes
organized in rows. (c) 40× photomicrograph of malignant cartilage
demonstrating both the crowded conditions and the irregular
conﬁguration of the large nuclei in the malignant component.
presented with a nine-month history of mild pain and a
worsening limp, with two months of a palpably enlarging
pelvic osteochondroma. There was no prior history of malig-
nancy in the patient or his aﬀected family members. Imaging
studies revealed a 10 × 12 × 12 cm sessile osteochondroma
on the left posterior ilium of the pelvis. Much of the lesion
consisted of a 5-6 cm thick cartilaginous cap, metabolically
active as seen by uptake of gadolinium on T2 images in
an o d u l a r [ 30] or ring and arc enhancement pattern [33],
associated with a central iliac bony erosion (Figure 1).
Partial resection of the ilium was performed with
an intercalary pelvic allograft reconstruction. Microscopic
examination revealed a well-diﬀerentiated chondroid neo-
plasm composed of hyaline cartilage with diﬀuse myxoid
degeneration and areas of tumor necrosis, consistent with
a low-grade chondrosarcoma arising from an osteochon-
droma.Theareasconsideredtohaveprogressedcytologically
deviated from areas of the lesion that had features of an
osteochondroma (Figure 2). Invasion of the cortex of the
ilium was evident on gross sections (Figure 3). Four years
after resection the patient remains without clinical evidence
of metastatic or recurrent disease with serial imaging of the
pelvis and chest.Sarcoma 3
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Figure 3: (a) Gross tumor specimen revealing cartilage overlying cortex of the ilium. (b)Gross tumor specimen revealing cortical invasion
by cartilage.
(a) (b) (c) (d)
Figure 4:(a)Anteroposteriorradiographrevealsthelargeosteochondromaoftheleftdistalfemurina13-year-oldwithMO.(b)Lateralview
further depicts the size of the large osteochondroma of the left distal femur. (c) Six-month follow-up anteroposterior radiograph, illustrating
the obvious growth of the posterolateral lesion of the distal femur compared to the posteromedial osteochondroma, including erosion
into the posteromedial osteochondroma by the tumor (arrow). (d) Six-month follow-up lateral radiograph reveals irregular calciﬁcations
within the cartilage cap, cortical erosions, and indistinct osseous margins, all suggesting malignant progression of the posterolateral
osteochondroma of the distal femur.
2.2. Case 2. A healthy 13-year-old male with a family history
of MO and multiple osteochondromas ﬁrst noted in infancy
presented to an outside institution with a six-month history
of a painless, enlarging osteochondroma of the left distal
femur. The preoperative radiographic appearance of this
mass demonstrated a 10 × 10 × 7cm lesion with a sclerotic
margin at the distal femoral diaphysis displaying obvious
growth, with an apparent 50% increase in volume over the
preceding six months, including invasion of the cortex of the
stalk of a nearby osteochondroma (Figure 4). Due to rapid
growth of the lesion, incisional biopsy had been performed
at an outside institution. The pathologic diagnosis by
local pathologists, reference lab pathologists, and our own
pathologistwasconsistentwithalow-gradechondrosarcoma
arising in osteochondroma. The diagnosis was based on
architecturalandcytologicdeviationbeyondthespectrumof
osteochondroma combined with the clinical and radiologic
features. Additional imaging studies including MRI and CT
demonstrated stippling of the thickened cartilage cap and
apparentinvasionofthecortexoftheshaftofthefemur,with
periosteal new bone being evident, suggesting malignancy
(Figure 5). FDG PET images demonstrated heterogeneous
uptake within the lesion and an SUVmax of 1.6 in the inferior
portion of the lesion.
Adistalfemoralresectionandintercalaryallograftrecon-
struction were performed. At the time of resection, a 10cm
posterior distal femoral lesion with a large cartilaginous cap
(3.5 cm in thickness) was excised. Histopathologic examina-
tion revealed a well-diﬀerentiated chondroid neoplasm com-
posed of abundant hypercellular nodules of hyaline cartilage
consistent with a low-grade chondrosarcoma arising from
an osteochondroma (Figure 6), similar to ﬁndings noted on
biopsy.Thepatientremainsfreeofdistantorlocalrecurrence
nine years after resection.
3. Discussion
These two cases of chondrosarcomatous progression of an
osteochondroma in a skeletally immature patient reﬂect an
unusual and rarely reported complication of MO. Clinically,
the symptoms of malignant progression in adults are typ-
ically subtle with insidious onset followed by a period of
rapid growth of the tumor mass. Although pain, swelling,
andenlargementofthelesionmaybehallmarksofmalignant4 Sarcoma
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Figure 5: (a) CT scan includes both distal femurs prior to excision of osteochondromas. Contrast the benign appearance of the
osteochondroma on the patient’s right femur to the thickened cartilage cap with stippling on the left (arrow). (b) MRI includes the left
distal femur after resection of the benign posteromedial osteochondroma and biopsy of the posterior chondrosarcoma, with the thickened
cartilage cap and invasion of femoral cortex (arrow) evident.
(a) (b)
Figure 6: (a) Low-power (10×) photomicrograph of the low-grade chondrosarcoma includes cells that are more crowded (small arrow)
and disorganized (large arrow) than most osteochondromas. (b) High-power (40×) photomicrograph of chondrocytes of a low-grade
chondrosarcoma is often enlarged (small arrow), and binucleation is common (large arrow).
progression in adults, none are speciﬁc symptoms in the
growing child[1, 10, 34].
Histologic features of sarcomatous progression of carti-
lage neoplasms have traditionally included atypical, plump,
or double-nucleate chondrocytes, and hypercellularity of
tissues[35].Aslow-grademalignanciesmaydisplayapaucity
of hypercellular tissues and few plump, atypical or bizarre
nuclei, it is not possible to make the diagnosis of a low-
grade chondrosarcoma based upon histologic presentation
alone, though the recently described tumor marker BCL2
may be useful clinically to help distinguish the progression
of osteochondroma to low-grade chondrosarcoma [36].
The challenges of making the diagnosis of malignancy by
histologic evaluation were highlighted in a recent reliability
study for the grading of low-grade cartilage neoplasms,
which revealed a kappa coeﬃcient for interrater reliability
of less than 0.45 among nine recognized musculoskeletal
pathologists[37]. Additional clues, obtained through exam-
ining the clinical course and serial imaging studies, shared
by the pathologist, radiologist, and clinician are essential in
characterizing such low-grade cartilage tumors [38].
The radiographic features of malignant transformation
include loss of distinct and regular margins at the periphery
of the lesion, cortical erosion of the osseous stalk or base
of the lesion, and irregular or punctate calciﬁcations in
an enlarged cartilage cap [2, 28, 29, 33, 39]. In adults,
cartilage caps greater than 15–20mm in thickness typically
herald malignant transformation [2, 28], though exceptions
occur [8]. Thicknesses of cartilage caps of benign lesions
removed from children with MO have not been reported to
our knowledge. CT, static and dynamic MRI [30, 31], and
angiographic studies may aid in assessing the thickness of
the cartilage cap and displacement or involvement of local
vasculature [28] as well as identifying patterns often seen
in cartilage tumors with malignant progression. FDG-PET
imaging has not been uniformly informative in the work-up
for malignant transformation in MO. An SUVmax of 2.0 has
been reported as the cut-oﬀ above which chondrosarcoma-
tous progression of an osteochondroma has likely occurred,
though lesions with an SUVmax as low as 1.3 have been found
in Grade I chondrosarcomas [40, 41]. Obtaining bone scans
in the assessment of skeletally immature patients with MOSarcoma 5
is not recommended, as high metabolic activity of benign
osteochondromas is common and will not help distinguish
benign from malignant lesions [42].
The slow growth and low metastatic potential of sec-
ondary peripheral chondrosarcomas such as these suggest
the need for a cautious approach to treatment. Biopsy, which
is often diﬃcult to interpret, followed by excision may lead
to unnecessary additional surgery for the majority of these
lesions that are likely to be benign. For those biopsied lesions
that prove to be malignant, simple osteochondroma excision
may be intralesional, with a higher risk of recurrence as
well as progressive tumor dediﬀerentiation and metastases
over time [35].Carefulsurveillanceofworrisomeosteochon-
dromas using the imaging techniques described above may
allow for appropriately timed wide excisions, if necessary
[38]. Such a treatment approach has a lower risk for tumor
recurrence and may also decrease the risk of unnecessary
major surgery. We do not advocate biopsy of questionable
lesions unless the clinical history and multiple imaging
studies suggest an aggressive nature of the tumor.
Numerousstudiesdescribea10%–25%riskofmalignant
progression in MO. However, these represent select popula-
tions of patients who have undergone surgical resection of
benign or malignant osteochondromas, likely resulting in an
overestimation of the rate of malignancy. Clinically based
studies report much lower rates of malignant progression,
generally ranging from 0% to 5%[4, 6, 11]. Case reports
of patients 15 years of age or younger or with open physes
on radiographs with a diagnosis of MO and secondary
chondrosarcoma include at least six skeletally immature
patients[2, 9–11, 43, 44]. Malignant lesions occurred pri-
marily in the proximal femur and proximal humerus.
4. Conclusions
These two pediatric cases of chondrosarcoma in children
withMOpresentedwithgrosslyenlargingosteochondromas.
Both patients had lesions with cartilage caps greater than
35mm with punctate calciﬁcations. While there is no gold
standard imaging study to establish the presence of malig-
nancy in adults or children, serial radiographic imaging is
warranted for all large osteochondromas, particularly those
in high-risk locations (pelvis, proximal femur, and proximal
humerus). Routine use of CT and MRI scans should be
employed for cases of suspected malignancy to identify
cortical invasion by tumor and thickness and metabolic
activity of cartilage caps. With thorough evaluation and pre-
operative planning, wide excision and limb-sparing surgery
can provide eﬀective treatment, if necessary[8, 28]. The
overall risk of secondary chondrosarcoma in the MO patient
population is low, estimated to be less than 5%. Given the
rarity of chondrosarcoma in pediatric MO patients, the risk
of sarcomatous progression in skeletally immature patients
with MO is even lower than that seen in adults. Multicenter
longitudinal studies of patients with MO are necessary to
determine the age-related risk of secondary chondrosarcoma
and to identify more sensitive and speciﬁc associations with
malignant progression.
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